4.4 Article

Proceed with Caution: Off-label Ketamine Treatment for Major Depressive Disorder

期刊

CURRENT PSYCHIATRY REPORTS
卷 16, 期 12, 页码 -

出版社

SPRINGER
DOI: 10.1007/s11920-014-0527-z

关键词

Ketamine; Depression; Ethics; Consent; Safety

资金

  1. Alkermes
  2. AstraZeneca
  3. Bristol-Myers Squibb Company
  4. GlaxoSmithKline
  5. Guidepoint Global
  6. H. Lundbeck A/S
  7. MedAvante
  8. Merck and Co.
  9. Neuronetics, Inc.
  10. Ortho-McNeil Pharmaceuticals
  11. Pfizer
  12. Roche
  13. Shire US, Inc.
  14. Sunovion Pharmaceuticals, Inc.
  15. Takeda
  16. Eli Lilly Co.
  17. Forest Laboratories
  18. Otsuka
  19. Gerson Lehman Group

向作者/读者索取更多资源

Ketamine offers a promising new option for the treatment of depression, but its increasing off-label use is ethically and clinically inappropriate at the moment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据